Acute Radiation Esophagitis Caused by High-Dose Involved Field Radiotherapy with Concurrent Cisplatin and Vinorelbine for Stage III Non-small Cell Lung Cancer
Open Access
- 1 August 2013
- journal article
- research article
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 12 (4), 333-339
- https://doi.org/10.7785/tcrt.2012.500319
Abstract
Purpose of this study is to obtain dose-volume histogram (DVH) predictors and threshold values for radiation esophagitis caused by high-dose involved field radiotherapy (IFRT) with concurrent chemotherapy in patients with stage III non-small cell lung cancer (NSCLC). Thirty-two patients treated by 66 Gy/33 Fr, 72 Gy/36 Fr, and 78 Gy/39 Fr thoracic radiotherapy without elective nodal irradiation plus concurrent cisplatin and vinorelvine were reviewed. Acute radiation esophagitis was evaluated according to common terminology criteria for adverse events version 4.0, and correlations between grade 2 or worse radiation esophagitis and DVH parameters were investigated. Grade 0–1, 2, 3, and 4–5 of radiation esophagitis were seen in 11 (34.4%), 20 (62.5%), 1 (3.1%), and 0 (0%) of the patients, respectively. Multivariate analysis revealed that whole esophagus V35 is a predictor of radiation esophagitis (OR = 0.74 [95%CI; 0.60–0.91], p = 0.006). There is a significant difference (38.4% vs. 89.4%, p = 0.027) in the cumulative rates of acute esophagitis according to V35 values of more than 20% versus less. As compared with other factors concerning patient and tumor and treatment factors, V35 < 20% of the esophagus was an independent predictor (HR = 0.29 [95%CI; 0.09–0.85], p = 0.025). In conclusion, whole esophagus V35 < 20% is proposed in high-dose IFRT with concurrent chemotherapy for stage III NSCLC patients.Keywords
This publication has 31 references indexed in Scilit:
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410JNCI Journal of the National Cancer Institute, 2011
- Radiation Dose-Volume Effects in the EsophagusInternational Journal of Radiation Oncology*Biology*Physics, 2010
- Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and dosesRadiotherapy and Oncology, 2009
- Involved-Field Radiation Therapy for Inoperable Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Treatment of Non-small Cell Lung Cancer, Stage IIIBSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2007
- Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patientsAnnals of Oncology, 2006
- A model for decision making for the use of radiotherapy in lung cancerThe Lancet Oncology, 2003
- High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trialInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non–Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Response, toxicity, failure patterns, and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non–small-cell carcinoma of the lungInternational Journal of Radiation Oncology*Biology*Physics, 1998